Overall Survival Among Patients With De Novo Stage IV Metastatic and Distant Metastatic Recurrent Non-Small Cell Lung Cancer.

Chloe C Su,Julie T Wu,Eunji Choi,Nathaniel J Myall,Joel W Neal,Allison W Kurian,Henning Stehr,Douglas Wood,Solomon M Henry,Leah M Backhus,Ann N Leung,Heather A Wakelee,Summer S Han

JAMA network open（2023）

引用 0|浏览23

暂无评分

摘要

In this cohort study, patients with distant recurrent NSCLC had significantly better OS than those with de novo disease, and the latter group was associated with characteristics that may affect overall survival. This finding can help inform future clinical trial designs to ensure a balance for baseline patient characteristics.

查看译文

关键词

cell lung cancer,distant metastatic recurrent non–small,overall survival

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要